Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karla Eggert

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of Neurology|May 30, 2009
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practiceAstrid Larisch, Wolfgang H Oertel, Karla Eggert
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 11, 2016
[The Competence Network Parkinson (CNP)]Wolfgang H Oertel, Guenther Deuschl, Karla Eggert
Clinical Neuropharmacology|January 18, 2014
Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational studyKarla Eggert, Wolfgang H Oertel, Andrew J Lees, et al.
Journal of Neurology|December 8, 2010
Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trialAstrid Larisch, Alexander Reuss, Wolfgang H Oertel, et al.
Neurology|July 31, 2007
Rationale for transdermal drug administration in Alzheimer diseaseWolfgang Oertel, Joel S Ross, Karla Eggert, et al.
European Neurology|January 30, 2009
Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologistsKarla Eggert, Astrid Larisch, Richard Dodel, et al.
Clinical Neuropharmacology|May 27, 2010
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group studyVincent Ries, Roland Selzer, Tobias Eichhorn, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2005
Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphineBjörn Tackenberg, J Carsten Möller, Karla Eggert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 19, 2007
Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany)Karla Eggert, Ullrich Wüllner, Gisela Antony, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 17, 2009
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week studyKarla Eggert, Orjan Skogar, Khaled Amar, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of Neurology|May 30, 2009
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practiceAstrid Larisch, Wolfgang H Oertel, Karla Eggert
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 11, 2016
[The Competence Network Parkinson (CNP)]Wolfgang H Oertel, Guenther Deuschl, Karla Eggert
Clinical Neuropharmacology|January 18, 2014
Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational studyKarla Eggert, Wolfgang H Oertel, Andrew J Lees, et al.
Journal of Neurology|December 8, 2010
Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trialAstrid Larisch, Alexander Reuss, Wolfgang H Oertel, et al.
Neurology|July 31, 2007
Rationale for transdermal drug administration in Alzheimer diseaseWolfgang Oertel, Joel S Ross, Karla Eggert, et al.
European Neurology|January 30, 2009
Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologistsKarla Eggert, Astrid Larisch, Richard Dodel, et al.
Clinical Neuropharmacology|May 27, 2010
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group studyVincent Ries, Roland Selzer, Tobias Eichhorn, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2005
Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphineBjörn Tackenberg, J Carsten Möller, Karla Eggert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 19, 2007
Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany)Karla Eggert, Ullrich Wüllner, Gisela Antony, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 17, 2009
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week studyKarla Eggert, Orjan Skogar, Khaled Amar, et al.
Pageof 4